CanBas (4575) Reports Operating Loss of 1,358 Million Yen in Latest Financial Results

CanBas (4575) has released its latest financial results, reporting an operating loss of 1,358 million yen, an ordinary loss of 1,307 million yen, and a net loss of 1,308 million yen. Earnings per share (EPS) stood at -66.42 yen. As a research-and-development-driven biotech company with ongoing upfront investments, operating cash flow was recorded at -1,424 million yen.

On the other hand, the company maintains a robust financial foundation, highlighted by a high equity ratio of 90.2%. With zero interest-bearing debt (0.0 billion yen) and cash and cash equivalents of 1.45 billion yen, the company preserves financial stability despite accumulated retained earnings of -15.32 billion yen. For the year ended June 30, 2026, the ratio of ordinary profit or loss to average total assets was -54.2%, and return on equity (ROE) was -58.0%.

---

Correction (September 19, 2026)：The affected figures and reporting-period labels were corrected after checking the source disclosure. Source disclosure